Regulations.gov document
Controlled Correspondence Related to Generic Drug Development; Guidance for Industry…
Other · FDA-2014-D-1167 · posted Dec 22, 2022
Key facts
| Document ID | FDA-2014-D-1167-0025 |
|---|---|
| Title | Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Draft Guidance |
| Document type | Other |
| Subtype | Guidance |
| Agency | FDA |
| Docket | FDA-2014-D-1167 |
| Posted | Dec 22, 2022 |
| Comment period opens | Dec 22, 2022 |
| Comments due | Feb 22, 2023 |
At a glance
- No Open for comment
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: